Scilex Holding (SCLXW) Liabilities and Shareholders Equity (2020 - 2026)

Scilex Holding (SCLXW) recorded quarterly Liabilities and Shareholders Equity of $293.6 million in Q1 2026, down 19.55% quarter-over-quarter from $365.0 million in Q4 2025, and up 271.8% on a YoY basis from $79.0 million in Q1 2025.

Scilex Holding (SCLXW) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Scilex Holding's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $293.6 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
  • Liabilities and Shareholders Equity was $293.6 million for Q1 2026 at Scilex Holding, down from $365.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $365.0 million in Q4 2025 to a low of $79.0 million in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $138.4 million across 5 years, with a median of $101.3 million in 2023.
  • The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity tumbled 38.96% in 2023, then soared 292.65% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $86.5 million in 2022, then grew by 17.08% to $101.3 million in 2023, then declined by 8.25% to $93.0 million in 2024, then jumped by 292.65% to $365.0 million in 2025, then decreased by 19.55% to $293.6 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $293.6 million (Q1 2026), $365.0 million (Q4 2025), and $275.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 84.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 116.58 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 200.89 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 136.46 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 128.69 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 92.50 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 56.28 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 208.00 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 86.48 Bn
10 Scilex Holding - - 4.15 Mn 293.64 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 293.64 Mn
Dec 31, 2025 364.98 Mn
Sep 30, 2025 275.88 Mn
Jun 30, 2025 83.76 Mn
Mar 31, 2025 78.98 Mn
Dec 31, 2024 92.95 Mn
Sep 30, 2024 100.43 Mn
Jun 30, 2024 104.54 Mn
Mar 31, 2024 91.24 Mn
Dec 31, 2023 101.31 Mn
Sep 30, 2023 80.53 Mn
Jun 30, 2023 126.46 Mn
Mar 31, 2023 86.05 Mn
Dec 31, 2022 86.53 Mn
Sep 30, 2022 101.46 Mn
Jun 30, 2022 142.30 Mn
Mar 31, 2022 140.97 Mn
Dec 31, 2021 77.93 Mn
Sep 30, 2021 139.64 Mn
Jun 30, 2021 139.90 Mn